Market Cap : 272.65 B | Enterprise Value : 283.5 B | PE Ratio : 9.51 | PB Ratio : 3.13 |
---|
NYSE:PFE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:PFE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, Pfizer's PEG is 1. Pfizer's 5-Year EBITDA Growth Rate is 10.51. Pfizer's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2022 was $5.14. Therefore, the Peter Lynch Fair Value for today is $54.02.
As of today (2022-08-18), Pfizer's share price is $48.58. Pfizer's Peter Lynch fair value is $54.02. Therefore, Pfizer's Price to Peter Lynch Fair Value Ratio for today is 0.90.
The historical rank and industry rank for Pfizer's Peter Lynch Fair Value or its related term are showing as below:
During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of Pfizer was 19.64. The lowest was 0.90. And the median was 1.99.
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
The historical data trend for Pfizer's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Pfizer's Peter Lynch Fair Value, along with its competitors' market caps and Peter Lynch Fair Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Pfizer's Peter Lynch Fair Value distribution charts can be found below:
* The bar in red indicates where Pfizer's Peter Lynch Fair Value falls into.
Pfizer's Peter Lynch Fair Value for today is calculated as
Peter Lynch Fair Value | = | PEG Ratio | * | 5-Year EBITDA Growth Rate | * | EPS without NRI (TTM) |
= | 1 | * | 10.51 | * | 5.14 | |
= | 54.02 |
Pfizer's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.14.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 10.51 instead of 15 in this case.
Pfizer's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value | = | Share Price | / | Peter Lynch Fair Value |
= | 48.58 | / | 54.02 | |
= | 0.90 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Pfizer's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Denton David M | officer: Chief Financial Officer & EVP | 1000 LOWE'S BOULEVARD MOORESVILLE NC 28117 |
Pao William | officer: Executive Vice President | C/O CORPORATE SECRETARY 235 EAST 42ND STREET NEW YORK NY 10017 |
Mcdermott Michael | officer: Executive Vice President | C/O PFIZER INC. CORPORATE SECRETARY 235 EAST 42ND STREET 235 EAST 42ND STREET NY 10017 |
Malik Aamir | officer: Executive Vice President | C/O PFIZER INC. CORPORATE SECRETARY 235 EAST 42ND STREET NEW YORK NY 10017 |
Carapezzi William R Jr | officer: Executive Vice President | 600 MOUNTAIN AVENUE MURRAY HILL NJ 07921 |
Sahni Payal | officer: Executive Vice President | ATTN: PFIZER CORP. SECRETARY 235 EAST 42ND ST. NEW YORK NY 10017 |
Desmond-hellmann Susan | director | 513 PARNASSUS AVENUE S126 SAN FRANCISCO CA 94143 |
Hockfield Susan | director | GENERAL ELECTRIC COMPANY 41 FARNSWORTH STREET BOSTON MA 02210 |
Damico Jennifer B. | officer: SVP & Controller | C/O PFIZER INC. CORPORATE SECRETARY 235 EAST 42ND STREET NEW YORK NY 10017 |
Quincey James | director | THE COCA-COLA COMPANY ONE COCA-COLA PLAZA ATLANTA GA 30313 |
Gottlieb Scott | director | MOLECULAR INSIGHT PHARMACEUTICALS 160 SECOND STREET CAMBRIDGE MA 02142 |
Fonseca Lidia | officer: Executive Vice President | 358 SOUTH MAIN STREET BURLINGTON NC 27215 |
Goettler Michael | officer: Group President | 1000 MYLAN BOULEVARD CANONSBURG PA 15317 |
Rogers Dawn | officer: Executive Vice President | 235 EAST 42ND STREET NEW YORK NY 10017 |
Littman Dan R. | director | ATTN: CORPORATE SECRETARY PFIZER INC. 235 E. 42ND ST NEW YORK NY 10017 |
From GuruFocus
Other Sources
By Zacks 2022-03-30
By Fool 2022-04-05
By Zacks 2022-03-25
By Zacks 2022-03-23
By Zacks 2022-04-04
By tipranks.com 2022-04-01
By Zacks 2022-03-30
By Zacks 2022-04-04
By Fool 2022-04-06
By Zacks 2022-04-01
By Zacks 2022-03-23
By Zacks 2022-03-25